U.S. Medicine Magazine features CyPath Lung, citing potential $895M savings and 92% sensitivity

bioAffinity Technologies, Inc.

CyPath Lung featured in U.S. Medicine pulmonary issue, highlighting improved lung cancer detection for veterans.
Economic modeling shows up to $895M savings for private payers, $379M for Medicare if used in 2022 standard of care.
Clinical performance: 92% sensitivity, 87% specificity, 88% accuracy in nodules ≤20 mm.
Case studies report Stage 1A detection when PET/CT, serum markers, and risk models failed.
Study authored by BAMC and VA pulmonologists, supporting integration into VA standard of care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.